Ticker

Cambridge, Massachusetts--(Newsfile Corp. - April 13, 2026) - ProMIS Neurosciences, Inc. (NASDAQ: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disease (AD) and other neurodegenerative disorders, today announced that Neil Warma, Chief Executive Officer, will participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference. The conference is being held…

PRECISE-AD Phase 1b trial fully enrolled. Completion of six-month assessments expected in Q2 2026 with blinded interim analysis anticipated early Q3 2026; twelve-month top-line data anticipated in early 2027 PMN310 continues to demonstrate a favorable safety profile, with no treatment-related serious adverse events reported to date Cambridge, Massachusetts,, March 25, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences…

Promis Neurosciences (NASDAQ: PMN - Get Free Report) is expected to be releasing its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect Promis Neurosciences to post earnings of ($4.22) per share for the quarter. Investors can find conference call details on the company's upcoming Q4 2025 earning report page for the

Cambridge, Massachusetts, March 18, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disease (AD) and other neurodegenerative disorders, today announced that it will present two scientific posters at the Alzheimer's & Parkinson's Diseases Conference (AD/PD™ 2026), being held March 17–21, 2026 in Copenhagen,…

Ally Bridge Group NY LLC increased its position in Promis Neurosciences (NASDAQ: PMN) by 367.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,233,497 shares of the company's stock after buying an additional 4,899,069 shares during the quarter. Promis Neurosciences